research Uncommon Presentation of Pityriasis Rubra Pilaris of the Scalp: Clinical, Trichoscopic, and Histopathologic Features and Review of the Literature
Recognizing scalp symptoms in PRP is crucial for proper diagnosis and treatment.
Search
for
Sort by
Research
210-240 / 1000+ results 
research Recalcitrant lichen planopilaris treated with upadacitinib: a case series
Upadacitinib may effectively treat resistant lichen planopilaris.
research Aim to alleviate alopecia areata with newly available agents
New treatments like JAK inhibitors offer hope for better alopecia areata management.
research Novel investigational drugs for alopecia areata and future perspectives
JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
research Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
research Reporte de caso: alopecia areata universal tratada exitosamente con baricitinib
Baricitinib successfully treated severe hair loss.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: A Retrospective Case Series and Literature Review
Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
research Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
People with alopecia areata may have a higher risk of blood clots.
research An Overview about Alopecia Areata Etiopathogenesis, Diagnosis, and Management: Review Article
Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Systemic immunotherapies
Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.
research A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata
Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
research Review of efficacy of baricitinib in the treatment of alopecia areata
Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
research Baricitinib for alopecia areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research Pattern hair loss distribution: a novel presentation for alopecia areata
Tofacitinib helped regrow hair in a teen with a unique pattern of alopecia areata.
research 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research DataSheet2_Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.PDF
New therapies like JAK inhibitors and stem cells show promise in treating vitiligo.
research Acne exacerbation after tofacitinib treatment for alopecia areata
Tofacitinib, a hair regrowth treatment, may worsen acne.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
research Hair today, gone tomorrow
Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
research Pathomechanisms of immune-mediated alopecia
The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.
research Personalized Medicine in the Field of Inflammatory Skin Disorders
Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.
research S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support
Use topical corticosteroids for alopecia areata, consider systemic treatments like corticosteroids or JAK inhibitors for severe cases, and inform about cosmetic options.
research Psychophysiological Mechanisms of Stress Impact on Hair Loss Processes
Stress causes hair loss by disrupting hair growth cycles, and combining medical and cosmetic treatments can help manage it.
research Title Choice of treatment for severe forms of alopecia areata (case reports)
JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
research The changing landscape of managing hair loss: a 30‐year perspective
There have been major advances in diagnosing and treating hair loss over the last 30 years, with new drugs and improved hair transplant techniques.
research Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.